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Abstract
Background: It has recently been shown that non-high density lipoprotein cholesterol (non-HDL-C) may be a
better predictor of cardiovascular risk than low density lipoprotein cholesterol (LDL-C). Based on known ethic
differences in lipid parameters and cardiovascular risk prediction, we sought to study the predictability of attaining
non-HDL-C target and long-term major adverse cardiovascular event (MACE) in Thai patients after acute myocardial
infarction (AMI) compared to attaining LDL-C target.
Methods: We retrospectively obtained the data of all patients who were admitted at Maharaj Nakorn Chiang Mai
hospital due to AMI during 2006–2013. The mean non-HDL-C and LDL-C during long-term follow-up were used
to predict MACE at each time point. The patients were classified as target attainment if non-HDL-C <100 mg/dl
and/or LDL-C <70 mg/dl. The MACE was defined as combination of all-cause death, nonfatal coronary event and
nonfatal stroke.
Results: During mean follow-up of 2.6 ± 1.6 years among 868 patients after AMI, 34.4% achieved non-HDL-C target,
23.7% achieved LDL-C target and 21.2% experienced MACEs. LDL-C and non-HDL-C were directly compared in
Cox regression model. Compared with non-HDL-C <100 mg/dl, patients with non-HDL-C of >130 mg/dl had
higher incidence of MACEs (HR 3.15, 95% CI 1.46–6.80, P = 0.003). Surprisingly, LDL-C >100 mg/dl was associated
with reduced risk of MACE as compared to LDL <70 mg/dl (HR 0.42, 95% CI 0.18–0.98, p = 0.046) after direct
pairwise comparison with non-HDL-C level.
Conclusions: Non-attaining non-HDL-C goal predicted MACE at long-term follow-up after AMI whereas non-attaining
LDL-C goal was not associated with the higher risk. Therefore, non-HDL-C may be a more suitable target of dyslipidemia
treatment than LDL-C in patients after AMI.
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Background
It is well-established that low-density lipoprotein choles-
terol (LDL-C) is an important risk factor for coronary
heart disease. The international guidelines recommend
LDL-C as a primary target of therapy in persons with
hypercholesterolemia and non-high-density lipoprotein
cholesterol (non-HDL-C) as a secondary target of ther-
apy in persons with triglyceride at least 200 mg/dl [1, 2].
Previous epidemiologic studies have shown that non-
HDL-C is more strongly associated with coronary heart
disease risk than LDL-C [3–5]. In addition, recent post-
hoc analyses have demonstrated that the on-treatment
level of non-HDL-C is more closely associated with
cardiovascular outcome than levels of LDL-C. These
findings suggest that the residual risk after lipid-
lowering treatment may be better quantified by non-
HDL-C than by LDL-C [6].
A number of studies have shown that there are ethnic
differences in risk prediction of coronary artery disease.
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The Framingham prediction model accurately predicts
the coronary artery disease risk among Caucasians and
blacks living in the United States, however, it overesti-
mates the risk in South-East Asians [7]. In addition,
the data from the Electricity Generating Authority of
Thailand (EGAT) cohort study showed that only HDL-
C was negatively associated with cardiovascular disease
mortality [8]. However, triglyceride and LDL-C were
not associated with cardiovascular death in Thai popu-
lation, which was inconsistent with previous studies in
other ethnic populations [9]. Although a growing body
of evidence supports that non-HDL-C is superior to
LDL-C in predicting long-term cardiovascular risk,
there is limited data in South-East Asian population.
Based on known ethic differences in lipid parameters
and cardiovascular risk prediction, we sought to study
the predictability of attaining non-HDL-C target and
long-term cardiovascular outcome in Thai patients after




This is a retrospective cohort study. The 868 patients
admitted in Maharaj Nakorn Chiang Mai hospital with a
diagnosis of AMI during a period of 2006–2013 were
enrolled into the study. The patients who did not have
lipid profile data during the treatment and patients who
had a follow-up period less than 3 months were ex-
cluded from the study.
The primary objective of the study was to assess the
predictability of attaining non-HDL-C goal and LDL-C
goal on the long-term major adverse cardiovascular
events (MACE) occurrence in patients after AMI. The
secondary objective of the study was to identify other
predictors of long-term MACE occurrence in patients
after AMI.
The study protocol was approved by the Medical Ethics
Committee of Faculty of Medicine, Chiang Mai University.
Definitions
▪ Acute myocardial infarction:
– Typical rise and/or fall of biochemical markers
of myocardial necrosis with at least one of the
followings:
a. Ischemic symptoms
b. Development of pathologic Q waves in
the ECG
c. Electrocardiographic changes indicative of
ischemia (ST-segment elevation or depression)
d. Imaging evidence of new loss of viable
myocardium or new regional wall motion
abnormality
▪ Major adverse cardiovascular outcomes
– Defined as a composite outcome of all-cause death,
myocardial infarction, stroke and cardiovascular
hospitalization.
▪ Achieved target of non-HDL-C and LDL-C
– The patients were classified as achieving target if the
mean non-HDL-C was less than 100 mg/dL and/or
the mean LDL-C was less than 70 mg/dl.
– The patients were classified as failure to achieve
target if the mean non-HDL-C was more than
130 mg/dL and/or the mean LDL-C was more
than 100 mg/dl.
Data collection
The medical records of patients diagnosed with AMI
and admitted in the hospital during 2006–2013 were
reviewed. Data from medical record included baseline
characteristic, cardiovascular risk, diagnostic data of
AMI, lipid parameters, and MACE outcomes. Lipid pa-
rameters used in the data analysis included LDL-C and
non-HDL-C. In this analysis, we examined the relation-
ship between the lipid parameters at admission, the
mean lipid parameters during long-term follow-up and
cardiovascular outcomes (Additional file 1).
Statistical analysis
Differences between continuous variables were assessed
using an unpaired 2-tailed t test for normally distributed
continuous variables and the Mann-Whitney test for
skewed variables. Proportions were compared by Chi-
square test or Fisher exact test when appropriate. The
recurrence— free survival curve was plotted via the
Kaplan-Meier method with the statistical significance ex-
amined by the log-rank test. Multivariate Cox regression
analysis was performed for variables with a p value of
less than 0.1 in univariate analysis. All statistical signifi-
cances were set at p value <0.05 and all statistical ana-
lyses were carried out by SPSS 17.0 (SPSS Inc. USA).
Results
Between 2006 and 2013, there were 868 patients admit-
ted due to AMI and enrolled into the study. The mean
age was 63 ± 11 years. There was higher prevalence of
male (62%) in this population. Majority of patients pre-
sented with acute ST-segment elevation MI (STEMI).
There were 20.9% presented with non-ST-segment eleva-
tion MI (non-STEMI) and only 1.5% presented with un-
stable angina. Among 674 patients who had ST-elevation
MI, 399 (59.2%) patients underwent primary PCI, 222
(32.9%) patients received fibrinolytic therapy while 53
(7.9%) did not receive reperfusion therapy. All patients
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had been receiving antiplatelets. Beta-blocker, angioten-
sin converting enzyme inhibitor (ACEI) and angiotensin
receptor blocker (ARB) had been prescribed in 79.7%,
64.9% and 28.0% of the patients, respectively.
During a mean follow-up of 2.6 ± 1.6 years, patients
had lipid parameter evaluation according to their physi-
cians and the mean interval of lipid parameters follow-
up was 6.5 ± 7.5 months. Among 868 patients, 23.7%
achieved LDL-C target and 34.4% achieved non-HDL-C
target. Table 1 shows the baseline characteristics of the
three groups as defined by their LDL-C level: <70 mg/dl,
70–100 mg/dl, and >100 mg/dl. Table 2 shows the base-
line characteristics of the three groups as defined by
their non-HDL-C level: <100 mg/dl, 100–130 mg/dl, and
>130 mg/dl. The patients who attained either LDL-C
target or Non-HDL-C target were significantly older and
had higher prevalence of chronic kidney disease, com-
pared to those who did not attain the corresponding
target. In addition, the baseline LDL-C and baseline
non-HDL-C were significantly lower in those with
attaining either LDL-C or non-HDL-C target. Statin had
been prescribed in 93.0% of the patients, similarly across
different LDL-C and non-HDL-C groups. Ezetimibe had
been prescribed in addition to statin in 3.9% of the pa-
tients. There was a higher proportion of patients with
mean LDL-C >100 mg/dl receiving ezetimibe compared
to those with lower LDL-C level (Tables 1 and 2).
During follow up, total MACE occurred in 184
(21.2%) patients. There were 25.2, 19.0 and 21.4% of pa-
tients developed MACEs in group of LDL-C <70 mg/dl,
LDL-C 70–100 mg/dl and LDL >100 mg/dl respectively.
There were 20.1, 18.9 and 25.8% of patients developed
MACEs in group of non-HDL-C <100 mg/dl, non-HDL-C
100–130 mg/dl and non-HDL-C >130 mg/dl respectively.
We first examined the predictability of LDL-C and
long-term MACEs and the predictability of non-HDL-C
and long-term MACEs individually. After cox regression
analysis adjusted with age, gender, comorbidities, and
baseline lipid parameters, patients with LDL70–100 mg/dl
and LDL >100 mg/dl had neutral risk of long-term
MACEs with the adjusted HR of 0.98 (95% CI 0.57–1.60)
and 1.02 (95% CI 0.56–1.84), compared to patients with
LDL-C <70 mg/dl. On the contrary, we found that non-
attaining non-HDL-C goal could predict the risk of long-
term MACEs. Compared to patients with non-HDL-C
<100 mg/dl, those with non-HDL-C 100–130 mg/dl had a
non-significantly increased risk of MACEs (adjusted HR
1.10; 95% CI 0.65–1.85) and those with non-HDL-
C >130 mg/dl had significantly higher risk of long-term
MACEs (adjusted HR 1.75; 95% CI 1.02–3.00, P = 0.04).
Then, we directly compared the strengths of the associ-
ation of LDL-C and non-HDL-C with long-term MACEs
by including LDL-C and non-HDL-C in the Cox model
simultaneously. We demonstrated the stronger association
Table 1 Baseline characteristics of patients among different mean LDL-C groups
Parameter LDL-C <70 mg/dl
(N = 206, 24% )
LDL-C 70–100 mg/dl
(N = 405, 46%)
LDL-C >100 mg/dl
(N = 257, 30%)
P-value
Age (years) 66.0 ± 11.2 63.3 ± 11.0 60.7 ± 11.1 <0.001
Male 65.6% 62.2% 58.7% 0.312
Body mass index (kg/m2) 22.5 ± 4.4 22.8 ± 4.5 23.5 ± 5.2 0.122
LVEF (%) 50.0 ± 13.8 50.1 ± 13.8 50.9 ± 14.0 0.772
Creatinine (mg/dl) 2.2 ± 10.2 1.6 ± 2.2 1.7 ± 7.6 0.492
Hemoglobin (g/dl) 12.5 ± 2.8 12.4 ± 2.1 12.7 ± 2.0 0.224
Baseline LDL-C (mg/dl) 97.3 ± 38.5 111.2 ± 39.0 135.3 ± 44.0 <0.001
Baseline non-HDL-C (mg/dl) 121.9 ± 39.5 137.5 ± 43.9 162.7 ± 48.6 <0.001
Baseline HDL-C (mg/dl) 40.4 ± 11.3 39.2 ± 11.6 40.4 ± 9.6 0.322
Smoking 38.0% 35.6% 37.4% 0.714
Hypertension 61.2% 57.3% 53.3% 0.222
Dyslipidemia 29.6% 30.4% 38.1% 0.978
Diabetes mellitus 30.1% 27.4% 24.1% 0.348
Chronic kidney disease 9.7% 7.9% 3.9% 0.039
History of CAD 10.2% 8.9% 12/1% 0.419
History of stroke 4.9% 4.2% 4.7% 0.921
STEMI 78.0% 80.0% 73.7% 0.190
Statin 92.2% 93.8% 92.2% 0.65
Ezetimibe 2.4% 2.5% 7.4% 0.003
CAD coronary artery disease, LVEF left ventricular ejection fraction, STEMI ST elevation myocardial infarction
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between non-HDL-C and long-term MACEs after the
direct comparison with LDL-C. Compared to non-HDL-
C <100 mg/dl, patients with non-HDL-C >130 mg/dl tri-
pled the risk of long-term MACEs (adjusted HR 3.15, 95%
CI 1.46–6.80, P = 0.003). Conversely, LDL-C >100 mg/dl
was inversely associated with the long-term MACEs when
compared to LDL <70 mg/dl (adjusted HR 0.42, 95% CI
0.18 – 0.98, p = 0.046) (Table 3 and Fig. 1). With this re-
gard, we demonstrated that for a given non-HDL-C level,
an increase in LDL-C was associated with a reduced risk
of long-term MACEs. Due to the possibility of the
correlation between LDL-C and non-HDL-C, we per-
formed the collinearity analysis for variance inflation fac-
tor (VIF) and demonstrated no collinearity between LDL-
C and non-HDL-C.
The association between the incidence of MACEs and
the frequency that the patients achieved LDL or Non-
HDL targets during the long-term follow-up were also
examined. The patients with long-term MACEs had
similar percentage of dosage on Non-HDL target com-
pared to those without long-term MACEs (31.0 ± 31.4%
vs. 29.1 ± 32.3%, P = 0.496). On the contrary, patients
Table 2 Baseline characteristics of patients among different mean non-HDL-C groups
Parameter Non-HDL-C <100 mg/dl
(N = 299, 34%)
Non-HDL-C 100–130 mg/dl
(N = 333, 38%)
Non-HDL-C >130 mg/dl
(N = 236, 27%)
P-value
Age (years) 65.9 ± 11.0 62.5 ± 11.1 60.6 ± 11.0 <0.001
Male 66.2% 60.1% 59.3% 0.173
Body mass index (kg/m2) 22.5 ± 4.5 23.0 ± 5.5 23.4 ± 3.9 0.252
LVEF (%) 49.9 ± 14.4 50.8 ± 13.0 50.0 ± 14.2 0.715
Creatinine (mg/dl) 2.1 ± 8.7 1.7 ± 6.8 1.4 ± 2.2 0.528
Hemoglobin (g/dl) 12.5 ± 2.5 12.5 ± 2.1 12.6 ± 2.0 0.681
Baseline LDL-C (mg/dl) 101.1 ± 38.5 116.1 ± 39.6 131.7 ± 46.1 <0.001
Baseline non-HDL-C (mg/dl) 122.1 ± 38.7 142.1 ± 42.5 164.3 ± 51.4 <0.001
Baseline HDL-C (mg/dl) 39.7 ± 11.3 40.2 ± 11.0 39.8 ± 10.5 0.822
Smoking 37.8% 35.0% 38.6% 0.850
Hypertension 57.9% 59.2% 53.8% 0.477
Dyslipidemia 25.8% 34.2% 38.6% 0.0.05
Diabetes mellitus 27.1% 26.4% 28.0% 0.920
Chronic kidney disease 9.0% 5.4% 7.2% 0.210
History of CAD 8.4% 9.0% 14.0% 0.07
History of stroke 5.0% 3.9% 4.7% 0.788
STEMI 79.3% 79.9% 72.5% 0.181
Statin 93.0% 92.8% 93.2% 0.981
Ezetimibe 3.3% 2.4% 6.8% 0.024
CAD coronary artery disease, LVEF left ventricular ejection fraction, STEMI ST elevation myocardial infarction




95% CI P-value Adjusted
hazard ratiob
95% CI P-value
LDL-C <70 mg/dl 1.00 1.00
LDL-C 70–100 mg/dl 0.98 0.57–1.60 0.934 0.74 0.39–1.40 0.350
LDL-C >100 mg/dl 1.02 0.56–1.84 0.956 0.42 0.18–0.98 0.046
Non-HDL-C <100 mg/dl 1.00 1.00
Non-HDL-C 100–130 mg/dl 1.10 0.65–1.85 0.715 1.40 0.74–2.65 0.304
Non-HDL-C >130 mg/dl 1.75 1.02–3.00 0.04 3.15 1.46–6.80 0.003
aIndividual relationships of LDL-C, non-HDL-C and time to the first major adverse cardiovascular events calculated by a Cox proportional hazard model with
adjustment for age, sex and comorbidities
bDirect pairwise comparison of LDL-C, non-HDL-C and time to the first major adverse cardiovascular events calculated by a Cox proportional hazard model with
adjustment for age, sex and comorbidities
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with long-term MACEs had higher percentage of dosage
on LDL target than those without long-term MACEs
(27.2 ± 28.8% vs. 20.6 ± 28.8%, P = 0.006).
Furthermore, the other independent predictors of
long-term MACEs were observed. After adjustment with
covariates, we found that age, the lower left ventricular
ejection fraction (LVEF) and non-STEMI were also the




Our study demonstrated that (1) relatively low propor-
tion of patients after AMI achieved lipid treatment goal.
Only 24% and 34% of patients after AMI attained LDL-
C goal and non-HDL-C goal during long-term follow-
up. (2) After cox regression analysis, we demonstrated
that non-attaining non-HDL-C goal was associated with
higher risk of long-term MACE, whereas the non-
attaining LDL-C goal was not associated with the
increased risk of long-term MACE. (3) The other inde-
pendent predictors of long-term MACE were age,
impaired LVEF and non-STEMI.
Pharmacologic lipid management after AMI is cru-
cial for secondary prevention of cardiovascular events
[10–12]. We observed that the low proportion of our
studied population could attain lipid target goal during
long-term follow-up. Therefore, aggressive lipid-lowering
treatment should be reinforced in order to achieve the
therapeutic target which may lead to the lower risk of
long-term MACE in this high-risk population.
Non-HDL-C composites of all atherogenic apolipo-
protein B-containing lipoproteins, including LDL-C,
very low-density lipoprotein cholesterol (VLDL-C),
intermediate-density lipoprotein cholesterol (IDL-C),
lipoprotein(a), chylomicrons, and chylomicron rem-
nants [4]. Therefore, non-HDL-C is a more compre-
hensive measure of atherogenic particles than LDL-C.
Previous studies have investigated the relationships
between LDL-C or non-HDL-C and the risk of coronary
heart disease. The Health Professionals Follow-up Study
showed that non-HDL-C was more strongly associated
with coronary heart disease risk than LDL-C [5]. Simi-
larly, the Framingham Heart Study showed that at every
non-HDL-C level, the concentration of LDL-C was not
associated with the risk for coronary heart disease. On
the contrary, at every LDL-C level, a strong positive and
graded association between non-HDL-C and risk of
coronary heart disease was observed [13]. In addition,
Liu et al. showed that coronary heart disease risk in
patients with diabetes was significantly associated with
increasing non-HDL-C, but not with increasing LDL-C.
They concluded that among patients with diabetes, non-
HDL-C was a stronger predictor of coronary heart
disease death than LDL-C [3].
A number of studies have shown that there are ethnic
differences in risk prediction of coronary artery disease
as well as response to treatment [7–9, 14]. In the present
study, we demonstrated that Thai patients who did not
attain non-HDL-C goal had higher risk of long-term
MACE, compared to those who attained non-HDL-C
goal. Our findings were in accordance with other studies
of western population. Interestingly, we observed that
non-attaining LDL-C goal did not correlate with the
long-term risk of MACEs. Counter intuitively, patients
with mean LDL-C >100 mg/dl had fewer cardiovascular
events than those with mean LDL-C <70 mg/dl after
direct pairwise comparison with non-HDL-C. This indi-
cated that for a given non-HDL-C level, an increase in
LDL-C was associated with a reduced risk of long-term
MACEs. It is well-established that the large LDL particle
is associated with the lower risk of cardiovascular events
than the small dense LDL particle [15]. The inverse
association between LDL-C and long-term MACEs ob-
served in the present study may be explained by the fact
that patients with higher LDL-C level had larger LDL
Fig. 1 Time to first major adverse cardiovascular events. Cox regression analysis of time to the first major adverse cardiovascular events after direct
pairwise comparison of LDL-C and non-HDL-C. a Time to first major adverse cardiovascular events among three different non-HDL-C groups. b Time
to first major adverse cardiovascular events among three different LDL-C groups
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particle size than those with lower LDL-C level after
adjustment with non-HDL-C level. Previous study by
Kastelein and colleagues reported similar findings that
LDL-C level after statin treatment was inversely associ-
ated with adverse cardiovascular outcome after direct
pairwise comparison with non-HDL-C level [6].
We demonstrated that non-HDL-C was a more accur-
ate predictor of long-term MACEs than LDL-C in our
population after AMI. As the non-HDL-C can be simply
calculated by subtracting HDL-C from total cholesterol,
therefore, measurement of non-HDL-C incurs no addi-
tional cost. With these regards, non-HDL-C should
favorably be used as a therapeutic target in the treatment
of dyslipidemia in patients after AMI. Our findings
support the recommendations from the international
atherosclerosis society and national institute of health
and care excellence (NICE) which favor the use of non-
HDL-C over LDL-C as targets of therapy [16, 17].
Conclusions
Non-attaining non-HDL-C goal was associated with
higher risk of long-term MACEs. However, we did not
find the correlation between non-attaining LDL-C goal
and the increased risk of MACEs. Therefore, non-HDL-C
may be a more suitable target of dyslipidemia treatment
than LDL-C in patients after AMI. In addition, we demon-
strated that only small proportion of patients after AMI
could achieve lipid targets during long-term follow-up.
More aggressive lipid-lowering strategy should be imple-
mented aiming to reduce the risk of cardiovascular out-
come in this high-risk population.
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